Zealand Pharma A/S Corporate Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst : Congrats for the approval. So a couple of questions from my side here. So maybe just sticking a little bit to the efficacy claims and the 10 minutes recovery time. So I'm not sure if I missed this, but is this something that you intend to chase in sort of a future head-to-head trial to sort of -- well, try to demonstrate some sort of superiority? And then maybe in addition to that, looking at the label compare, so nausea, vomiting is somewhat higher with Zegalogue compared to Gvoke, at least. So do you have any color why you actually see this somewhat material difference? And I'm just wondering whether it could be higher receptor occupancy or any connections with what you could say the beta, at least indicated beta, faster glucose recovery timeline, so with the 10 minutes. And then maybe just lastly, just on the ADAs. So the antibody -- sorry, antidrug antibodies. So I know less than 1% is -- in close to 500 patients seems somewhat modest. But is there any concerns or any comments made by the

Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst : Okay. Got it. And then maybe if I may follow-up just sort of a small commercial question here. So again, comparing the labels, so Gvoke and Baqsimi has a case for use of the drug between the age of level 2 and 4 and then you have 6. So can you maybe just -- how much impact or how much of the -- you would say, commercial upside, does that sort of leave the -- for competitors in that? I guess, it's a very small number of patients that are below 6. Is that correct?